Clin Osteol 2018; 23(4): 138-145

18-mesačná liečba teriparatidom zlepšuje u pacientov s glukokortikoidmi indukovanou osteoporózou hodnoty hustoty kostného minerálu a trabekulárne kostné skóre: výsledky prospektívneho sledovania (register OSTEO.sk)Original contributions

Payer Juraj1, Tomková Soňa2, Killinger Zdenko1, Brázdilová Kristina1, Jackuliak Peter1, Vaňuga Peter3, Letkovská Alexandra4, Masaryk Pavol4, Kmečová Zlata5, Kužma Martin1
1 Comenius University Medical Faculty, 5th Department of Internal Medicine, University Hospital Bratislava, Slovakia
2 Osteocentrum, Hospital Košice-Šaca, Košice, Slovakia
3 National Institute of Endocrinology and Diabetology, Lubochňa, Slovakia
4 National Institute of Rheumatic Diseases, Piešťany, Slovakia
5 Osteocentrum of F. D. Roosevelt Faculty Hospital, Banská Bystrica, Slovakia


Úvod:

L
iečba glukokortikoidmi má za následok rýchlu stratu denzity kostného minerálu (BMD) a glukokortikoidmi indukovaná osteoporóza (GIOP) je najčastejšou a závažnou formou sekundárnej osteoporózy. Liečba žien s post­menopauzálnou osteoporózou teriparatidom (TPTD) významne zvyšuje trabekulárny kostný objem a konektivitu, zlepšuje trabekulárnu morfológiu s posunom smerom k viac doštičkovitej štruktúre a zvyšuje hrúbku kortikálnej kosti.



Ciel štúdie:

Posúdení zmeny BMD a trabekulárneho kostného skóre (TBS) po 12 -⁠ a 18-mesačnej liečbe TPTD u pacientov s GIOP.

Pacienti a metódy:
Prospektívne multicentrické, nekontrolované sledovanie účinnosti a bezpečnosti liečby TPTD u pacientov s GIOP, uskutočňované v 5 špecializovaných centrách ustanovených pre liečbu TPTD. U všetkých pacientov zaradených do registru OSTEO.sk bolo pravidelne uskutočňované meranie BMD v bedrovej chrbtici a proximálnom femoru a sledovanie markerov kostného obratu. V podskupine účastníkov bolo merané TBS.



Výsledky:

Z celkového počtu 263 pacientov zaradených do registra bolo do záverečnej analýzy zahrnutých 129 pacientov (20 mužov vo veku 51,5 let/109 žien vo veku 59,7 let). Po liečbe TPTD bol zistený v porovnaní s východiskovými hodnotami nárast BMD v bedrovej chrbtici v 12. mesiaci (+ 8,3 %, p < 0,001) a v 18. mesiaci nárast BMD hlavica femoru (+ 3,85 %, p < 0,001), krčku femoru (+ 3,26 %, p < 0,001) a bedrovej chrbtice (+ 9,28 %, p < 0,001). V podskupine (n = 12) v priebehu prvých 12 mesiacov narástlo TBS o 2,4 % (p = 0,01). 18-mesačná liečba TPTD viedla k významnému zvýšení markerov kostného obratu.

Záver:
18-mesačná liečba TPTD viedla k významnému zvýšeniu BMD so súčasným zvýšením všetkých hodnotených markerov kostného obratu. Okrem toho bolo v podskupine účastníkov štúdie pozorované zvýšenie TBS po 12 mesiacoch liečby. Podľa týchto výsledkov bolo preukázané, že u pacientov s GIOP je TPTD vysoko účinný osteoanabolický liek.

Keywords: kostná minerálna denzita (BMD); osteoporóza indukovaná glukokortikoidmi (GIOP); trabekulárne kostné skóre (TBS); teriparatide

Published: December 11, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Payer J, Tomková S, Killinger Z, Brázdilová K, Jackuliak P, Vaňuga P, et al.. 18-mesačná liečba teriparatidom zlepšuje u pacientov s glukokortikoidmi indukovanou osteoporózou hodnoty hustoty kostného minerálu a trabekulárne kostné skóre: výsledky prospektívneho sledovania (register OSTEO.sk). Clinical Osteology. 2018;23(4):138-145.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13(10): 777-787. Dostupné z DOI: <http://dx.doi.org/10.1007/s001980200108>. Go to original source...
    2. Payer J, Brazdilova K, Jackuliak P. Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options. Drug Healthc Patient Saf 2010; 2 : 49-59. Go to original source...
    3. Dale Carbonare L, Arlot ME, Chavassieux PM et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001; 16(1): 97-103. Dostupné z DOI:<http://dx.doi.org/10.1359/jbmr.2001.16.1.97>. Go to original source...
    4. Van Staa TP, Leufkens HGM, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000; 39(12): 1383-1389. Go to original source...
    5. Van Staa T, Leufkens HGM, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15(6): 993-1000. Dostupné z DOI:<http://dx.doi.org/10.1359/jbmr.2000.15.6.993>. Go to original source...
    6. De Gregório LH, Lacativa PG, Melazzi AC et al. Glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metabol 2006; 50(4): 793-801. Go to original source...
    7. Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006; 79(3): 129-137. Dostupné z DOI:<http://dx.doi.org/10.1007/s00223-006-0019-1>. Go to original source...
    8. Migliaccio S, Brama M, Malavolta N. Management of glucocorticoids-induced osteoporosis: role of teriparatide. Ther Clin Risk Manag 2009; 5(2): 305-310. Go to original source...
    9. Lekamwasam S, Adachi JD, Agnusdei D et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012; 23(9): 2257-2276. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-012-1958-1>. Go to original source...
    10. Jiang Y, Zhao JJ, Mitlak BH et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18(11): 1932-1941. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.2003.18.11.1932>. Go to original source...
    11. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434-1441. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200105103441904>. Go to original source...
    12. Rizzoli R, Adachi JD, Cooper C et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2012; 91(4): 225-243. <http://dx.doi.org/10.1007/s00223-012-9630-5>. Go to original source...
    13. Uihlein AV, Leder BZ. Anabolic therapies for osteoporosis. Endocrinol Metab Clin North Am 2012; 41(3): 507-525. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ecl.2012.05.002>. Go to original source...
    14. Vanuga P, Tomkova S, Masaryk P et al. Slovak register of patient with severe osteoporosis on osteoanabolic treatment. Osteoporos Int 2012; 23(Suppl 2): S239-S240.
    15. Bultink IE, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Open Pharmacother 2013;14(2):185-97. Dostupné z DOI: <http://dx.doi.org/10.1517/14656566.2013.761975>. Go to original source...
    16. Amiche MA, Albaum JM, Tadrous M et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. Osteoporos Int 2016; 27(6): 1989-1998. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-015-3476-4>. Go to original source...
    17. Blick SK, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs 2008; 68(18): 2709-2737. Dostupné z DOI: <http://dx.doi.org/10.2165/0003495-200868180-00012>. Go to original source...
    18. Pothuaud L, Carceller P, Hans D. Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. Bone 2008; 42(4): 775-787. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2007.11.018>. Go to original source...
    19. Hans D, Goertzen AL, Krieg MA et al. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 2011; 26(11): 2762-2769. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.499>. Go to original source...
    20. Briot K, Paternotte S, Kolta S et al. Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: the OPUS study. Bone 2013; 57(1): 232-236. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bone.2013.07.040>. Go to original source...
    21. Boutroy S, Hans D, Sornay-Rendu E et al. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int 2013; 24(1): 77-85. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-012-2188-2>. Go to original source...
    22. Iki M, Tamaki J, Kadowaki E et al. Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: the Japanese Population-Based Osteoporosis (JPOS) cohort study. J Bone Miner Res 2014; 29(2): 399-407. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.2048>. Go to original source...
    23. Senn C, Gunther B, Popp AW et al. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int 2014; 25(7): 1945-1951. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-014-2703-8>. Go to original source...
    24. Saag KG, Agnusdei D, Hans D et al. Trabecular Bone Score in Patients With. Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. Arthritis Rheumatol 2016; 68(9): 2122-2128. Dostupné z DOI: <http://dx.doi.org/10.1002/art.39726>. Go to original source...
    25. Miyaoka D, Imanishi Y, Ohara M et al. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine. Bone Mineral Density and Microarchitecture in Osteoporosis. Calcif Tissue Int 2017; 101(4): 396-403. Dostupné z DOI: <http://dx.doi.org/10.1007/s00223-017-0295-y>. Go to original source...
    26. Saag KG, Zanchetta JR, Devogelaer JP et al. Effects of teriparatide versus alendronate for treating of glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60(11): 3346-3355. Dostupné z DOI: <http://dx.doi.org/10.1002/art.24879. Go to original source...
    27. Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357(20): 2028-2039. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa071408>. Go to original source...
    28. McClung MR, San Martin J, Miller PD et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005; 165(15): 1762-1768. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.165.15.1762>. Go to original source...
    29. Keaveny TM, Donley DW, Hoffmann PF et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007; 22(1): 149-157. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.061011>. Go to original source...
    30. O´Brien CA, Jia D, Plotkin LI et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strenght. Endocrinology 2004; 145(4): 1835-1841. <http://dx.doi.org/10.1210/en.2003-0990>. Go to original source...
    31. Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15(6): 1006-1013. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.2000.15.6.1006>. Go to original source...
    32. Reid DM, Adami S, Devogelaer JP et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69(4): 242-247. Go to original source...
    33. Neer RM, Claude DA, Jose RZ et al. Effect of Parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434-1441. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200105103441904>. Go to original source...
    34. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44(1): 202-211. Dostupné z DOI: <http://dx.doi.org/10.1002/1529-0131(200101)44 : 1<202::AID-ANR27>3.0.CO;2-W>. Go to original source...
    35. Sambrook PN, Kotowicz M, Nash P et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003; 18(5): 919-924. Dostupné z DOI: <http://dx.doi.org/10.1359/jbmr.2003.18.5.919>. Go to original source...
    36. Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67(4): 277-285. Go to original source...
    37. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(9): 1434-1441. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200105103441904>. Go to original source...
    38. Murphy DR, Smolen LJ, Klein TM et al. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskelet Disord 2012; 13 : 213. Dostupné z DOI: <http://dx.doi.org/10.1186/1471-2474-13-213> Go to original source...
    39. Bultink IEM, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: An update on current pharmacotherapy and future directions. Expert Opin Pharmacother 2013; 14(2): 185-197. Dostupné z DOI: <http://dx.doi.org/10.1517/14656566.2013.761975>. Go to original source...
    40. Gluer CC, Marin F, Ringe JD et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Rheumatol 2012; 39(3): 600-609.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.